Research Articles

Teva Pharmaceutical Has It All: Value, Growth and Yield

Julie C - Saturday, January 15, 2011
Headquartered in Israel, Teva (TEVA) is the world's largest generic drug maker, which markets over 1200 molecules in over 60 countries throughout the world. In addition to their generic portfolio, Teva also possesses a strong branded portfolio led by Copaxone, the world's leading injectable therapy for multiple sclerosis. Teva generates high levels of cash flow, has a very strong debt to equity ratio of 18% and therefore, has the scale and financial muscle to be more flexible and aggressive with their business model than most of their peers.
Strong History of Operating Excellence
The following historical F.A.S.T. Graph plots Teva’s earnings growth since calendar year 2000. Earnings growth in excess of 28% per annum was far in excess of any of its peers. The only blemishes on this excellent record were the flattening of earnings in 2007 and a slight drop of earnings in 2008. Both of these instances can be attributed to one-time charges, most of which were associated with the termination of a licensing agreement to distribute Copaxone by Sanofi-Aventis (SNY) as well as integration costs for several bolt on acquisitions that Teva made. However, core business remained strong as sales per share and cash flow per share both increased strongly during these years.

(Click to enlarge)
This next graph correlates monthly closing stock prices with Teva's earnings per share. Based on this price and earnings correlated graph, it appears that Teva’s stock price was undervalued for the last five years (since 2005). In other words, the black monthly closing stock price line is significantly below the orange earnings justified valuation line. However, as you'll soon see, there is more than meets the eye regarding these last five years' apparent undervaluation. This will become evident by shortening the time period that we measure.
(Click to enlarge)
This third of our graphs shortens the time frame measured to only five years (the graph says six years because it includes one year of forecasting). Because of the weakening of earnings-per-share growth during 2007 and 2008, Teva’s average earnings per share growth rate was reduced from over 28% per annum to just over 20% per annum. Although this is still strongly above-average earnings growth, the market applied a reduced normal PE ratio valuation of 16.6 (blue line with asterisks).
In theory at least, 20% growth would imply a PEG ratio valuation of 20 times earnings. However, there was clearly some pessimism built in to this lower than historically normal valuation. In addition to this reduced earnings growth rate, there are some additional concerns regarding competition and patent challenges to Teva's core branded drug Copaxone. With Teva's PE ratio currently under 12 times earnings, these issues are having a greater impact the closer we get to pending patent expiration for Copaxone in 2014 or potentially earlier. These issues will be expanded upon later in this report.
(Click to enlarge)
Our next historical price and earnings correlated graph on Teva adds in dividends (light blue shaded area stacked on top for visual perspective). Also, performance results are calculated for the period spanning calendar year 2002 to current, and include a dividend cash flow table. Even with their current valuation extremely low, Teva was able to significantly outperform the S&P 500 on both capital appreciation and total dividend income generated.
This is a real testament to the power of earnings growth, especially when you consider that Teva's current PE ratio of 11.9 is significantly below the S&P 500's current PE ratio of 15.2. This is especially confusing when you consider that Teva's compound earnings growth rate of 28.1% is more than five times faster than the S&P 500's earnings growth rate of 5.2% over this same time period. Somehow, this makes no sense to us at all.
(Click to enlarge)
Historical Concluding Remarks
When looked at from a historical perspective it seems that Teva does possess all three attributes listed in the title of this article. At 11.9 times earnings Teva trades at a significant discount to the 15.2 times earnings level that the S&P 500 (the general stock market) trades at. Consequently, Teva’s stock appears attractively valued today. Historical earnings growth of more than 28% per annum, which is more than five times the S&P 500 growth rate of 5.2%, depicts exceptional growth. Finally, Teva's current yield of 1.4% is only modestly below the S&P 500's current yield of 1.8%. However, thanks to growth yield (yield on cost) Teva has generated more than twice the total dividends that an equal investment in the S&P 500 would have generated since calendar year 2000. So Teva offers dividend growth and yield as well.
Historically Teva has generated very strong operating results that are far in excess of not only the S&P 500 but also far in excess of their industry peers as well. Over the same historical time frame, Merck & Co. only grew earnings at 3.5% and Pfizer (PFE) only grew earnings at 8.1%. Even the exalted Johnson & Johnson (JNJ) was only barely able to squeak into double digits with earnings growth of 10.4%. Therefore, it only seems justified that each of these three branded pharmaceutical behemoths are trading at historically low PE ratios. But Teva's low valuation seems onerous and unjustified given its record of consistent and high growth.
Thesis for Growth
Currently the Value Line investment survey forecasts that Teva will grow earnings per share at 15% or better through the years 2013 to 2015. Zacks Investment Research forecasts projected EPADS (operating earnings before nonrecurring items) growth for the next five years at 15%. The following graph's estimated earnings and return calculator depicts a consensus of 24 analysts reporting to FirstCall with an estimated five-year earnings growth rate of 13%. Therefore, a range of 13% to 15% future earnings growth is at least consistently expected. Most importantly, this is just under one half of their 11-year historical growth rate of 28.1% and lower than their last five years earnings growth rate of 20.4% (see our graphs above - both graphs include one year of forecast not calculated).
(Click to enlarge)
According to a presentation at the Credit Suisse 2010 healthcare conference on November 11, 2010, William Marth, president and CEO, presented the following targets for 2015 and the logic behind them. The following slides from his presentation summarize Teva’s guidance for future growth:
This first slide depicts revenue targets of $31 billion with net income of $6.8 billion, which represent net profitability of 22%.
(Click to enlarge)
This next slide shows that Teva expects a compounded annual growth rate of revenues of 14% per annum for the period 2009 to 2015. This would be consistent with the earnings forecasts presented above, assuming that earnings growth will correlate to revenue growth.
(Click to enlarge)
The next slide illustrates the growth potential of generics throughout the world from 2008 to 2015. Clearly, there is a huge opportunity in generics for Teva to target.
(Click to enlarge)
This slide shows the specific opportunity that Teva has for capturing their share of the growing market for generics.
(Click to enlarge)
This next slide illustrates Teva's expectations for growth in their branded portfolio out to 2015.
(Click to enlarge)
This slide provides more detail on how Teva expects to grow their branded business by utilizing a multifaceted approach. Take special note of the growth expected for biosimilars as this segment of their branded portfolio represents Teva’s strongest growth opportunity according to many analysts.
(Click to enlarge)
This final slide illustrates what Teva calls their loaded branded pipeline. Perhaps their most important candidate is Laquinimod, which would be their oral replacement for Copaxone, their current injectable blockbuster for treating multiple sclerosis.
(Click to enlarge)
Concluding Remarks Regarding Teva's Potential Growth
Teva's acquisition of Barr Pharma in December of 2008 established them as a major player in the generic pharmaceutical business in the U.S. and Europe. Recent smaller acquisitions such as Theramex and the European women's health business of Merck KGaA (MGKAY.PK) continue to diversify Teva's product lineup both geographically and by product. Teva's strong cash war chest and continuing high generation of cash flow provide them the financial flexibility and muscle to continue to make acquisitions, develop new branded products and to legally defend their product real estate.
However, Teva also faces several challenges and risks to their business model. The generic industry is highly fragmented especially in the potentially large markets such as China and India where low labor costs provide these countries a competitive advantage. Furthermore, their branded franchise drug Copaxone, which represents approximately 15% of their sales and as much as 30% of their operating profit, is facing numerous threats and challenges.
According to the analysts’ note dated January 13, 2011, MorningStar analyst Michael Waterhouse states that they believe that “Teva will use acquisitions to pursue its ambitions revenue and profit goals.” And as they always do, MorningStar ends their research reports with duelling Bulls and Bears commentary quoted below courtesy of MorningStar:

 

Bulls Say

As the largest pharmaceutical manufacturer with vertically integrated operations, Teva has the scale and resources to minimize the entry of low-cost producers.

Teva’s emergence as a hybrid generic/innovative pharmaceutical company allows for consistent stable cash flows with above-average profitability and growth.

Teva is probably one of the few generic firms with the financial resources and capability to enter the nascent biosimilars market.

Given the broad international focus on lowering medical costs, the demand for generics should continue to grow.

Teva’s low tax base leads to higher profitability and increased cash flow.

Bears Say

Copaxone loses U.S. patent protection in 2014. Lack of branded pharmaceutical replacement will hinder Teva’s profitability.

A jury recently upheld Pfizer’s litigation against Teva’s at-risk launch of generic Protonix. If ultimately penalized, Teva could face a substantial liability.

Teva faces considerable competition from low-cost producers in India and China. Aggressive entry pricing could weaken Teva’s dominant market position.

Government-mandated price cuts from austerity measures, particularly in Europe, could offset increases in generic drug utilization.

After 2013, the market values of patent expirations vastly decline, a disturbing fact for an industry dependent on sales of drugs losing patent protection.”

 

Summary and Conclusions
It is our opinion that at today's prices, Teva possesses the big three: attractive value, attractive growth and a reasonable and potentially growing dividend yield. Furthermore, we feel that the current low valuation unfairly discounts the future potential of this high-quality growth and income story.
We would agree that Teva will most likely not grow at the 20% to 30% rate that it historically has achieved. However, we believe that the company's ability to grow earnings at 15% or better is reasonable and above-average. Therefore, we believe that patient investors have an opportunity to achieve above-average long-term growth and increasing dividend income if purchased at today's historically low valuation. As always, we recommend that a comprehensive research effort be conducted.
Disclosure: I am long TEVA.
Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.
Comments
Anonymous commented on 18-Oct-2012 10:36 AM
I wanted to draft you the tiny word in order to thank you so much over again for your personal nice basics you've contributed here. This has been simply tremendously open-handed with you to provide extensively what exactly many individuals would have sold for an electronic book in making some dough for themselves, certainly given that you could have done it if you considered necessary. These creative ideas also acted as a good way to be certain that most people have the identical zeal much like my personal own to grasp very much more in regard to this problem. I believe there are many more pleasurable instances ahead for many who view your blog.
pokiespokiefree online casino
Anonymous commented on 18-Oct-2012 01:32 PM
Dead composed subject material , thankyou for selective information . sump pumps
Anonymous commented on 19-Oct-2012 02:51 AM
The must have summer
Canada Goose JacketsOutlet styles include the timeless denim and leather as well as cropped and trench-style style items.
Canada Goose Parkas Outletare great in winter for warmth; they can be great on different styles and can go with casual or formal looks.The
Canada Goose OutletExpedition Parka provides heavy-duty warmth thanks to its high-quality duck down insulation.It is not a novelty that military style tops the leading fashion trends
Canada Goose Jackets Outletdue to its refined and classic influences and qualities.
Anonymous commented on 19-Oct-2012 04:45 AM
Designs of this season give you the unlimited cool feelings in this cool summer. The new designs of Coach products in the Coach Outlet enrich our daily life.
Anonymous commented on 19-Oct-2012 10:54 AM
I understand that in Egyptian hieroglyphics Louis Vuitton Official Website the course of development from ideograms to phonetic writing can be studied.Regarding the craft,the goods fromCoach Outlet Store is tight,the seams are aligned and details emulate the designer's actual handbags.west plus southwest around the commune,Louis Vuitton Online Store is usually a pure gardening plus Commune.Coach Outlet Online The staff was adamant about the policy even though they acknowledged there was nothing stopping us from coming in the next day and purchasing from another shop girl.Louis Vuitton Outlet iphone cases I was excited to see this coat online since I love Louis Vuitton, and I needed a new coat like this.This Louis Vuitton Canada for sale belongs to the sounding just what are termed asLouis Vuitton vintage best sellers.
Anonymous commented on 19-Oct-2012 03:21 PM
F*ckin' awesome things here. I'm very glad to peer your article. Thanks so much and i am having a look forward to contact you. Will you kindly drop me a mail?SourceCheck Out Your URLFind Out Moreclick to read moreRead Full Report
Anonymous commented on 19-Oct-2012 07:38 PM

Anonymous commented on 21-Oct-2012 04:18 PM
I am continually looking online for ideas that can assist me. Thanks! halogen cooker
Anonymous commented on 22-Oct-2012 01:32 PM
I¡¦ve been exploring for a little for any high quality articles or weblog posts in this sort of space . Exploring in Yahoo I finally stumbled upon this website. Reading this information So i am glad to convey that I've an incredibly excellent uncanny feeling I came upon exactly what I needed. I such a lot for sure will make sure to do not omit this web site and give it a look on a relentless basis.casino
Anonymous commented on 22-Oct-2012 04:59 PM
I like this website very much, Its a rattling nice situation to read and get info . "The love of nature is consolation against failure." by Berthe Morisot.best dehumidifiers |best coffee grinder 2012 | Best Generator |best Humidifiers |leaf blowers | paint sprayers

Post a Comment




Captcha Image


Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”


Recent Posts


Tags

NOC DRC QCOR NKE SLW AVP HBI DORM EMR PCLN JWML.Y CBI ANDE BMRC FairlyValued SO GLT DECK UNM above-average JSFT GOOGL VRX TROW IR, RCII 3NSRGY LLL CAH KO PNR long portfolio COH AFL,CVX,ED,JNJ,MCD,PG,SWK,T,WMT,TGT,ABM,AFL,BEN,BMS,CB,CBSH,CTBI FUL EPHC TNC RIMM BBBY BKH JKHY diversified machinery REXX CTL dividendpaying PDFS PEG ACM HPQ MDP LO CGY TWX DRIP EV biotechnology MHP InformationTech HRS GME Telecommunications UTHR ED RMD DD stock WHR POT MSA macro MGEE food service growth stocks CBU OKE WFC DLPH IR CanadianBanks ConsumerDiscretionary FTR UTX DGX CACC ORI GPC machinery BWLD TUP SHOO dividendGrowth ITW, Aristocrats LXU CXRX RSO ETN MA long-term investing FC IBN HD HII dividends,earnings growth dividend growth COST JAZZ NEE Consumer discretionary PSX AOS HNZ fundamental stock research tool GD TU THFF SILVER URI EBAY AAPL CTAS THO ADT DKS ORCL VAL CPN long-term growth MAIN JCI BRLI WMT ALB CLF FDX FISV RY MSFT MUR NSC SXL CTBI SAVE SBRA long ideas CAM VZ DGAS dividend growth investing CAPE CM KR Contenders CR MGA MGRC BOFI mid-cap FairValuation TOT CSCO stockResearchTool LMT HCP PII MPW Dividend Champions PRAA HAS TGH BMS dividend MNST AFG STE OKS DLR EXC blue chip T UN fastgraphs AIRM TSCO investing for income,growth and income WAG GOLD PCP intrinsic value FOSL BEN consumer earnings growth EMC AMT IDA ESI fair value TICC CELG GE UHS investing for total return WIN MTW ARRS APEI SU TEVA MMM CATY short ideas TEG: WEC: PKG BAX BWP NSR SWKS LOW R AKRX SBR RDS.A ECHO LZB DividendAristocrats ARLP LQDT LLY Challengers SWK BIDU OHI highqualityR RSG,RTN ACN HGT FLO PPL FDO value-oriented BHP CTRX AVD VRTU EMR, MMM PEP WST Fundamentals EAT BIIB ATHM GrowthOriented BBY cyclical GPI DOV ICLR CFR ACR CRLI SRCE EnergySector DTV CACI PRXL SYK ULTA SoundValuation RBC MAT WGL interest rates value investing HSC PG NA SHPG SCHW dividend income CNSL PFG TEF sell NLY SHW KCAP KSS AGN long-term long-term returns stock analysis XEL MTZ AAP TGI treasury BRS STMP WSM stocks HCA earnings PPG AZZ BR Buffett PNM BF.B AAN VTR BNS. TSM HCI BMO M GPS WASH AFSI IPAR SPY SCG AMCX PortfolioDesign SFG ESRX SYY OHI,EPR,WPG,JLL ZUMZ DE SIVB Industrial Valuation BA Market Outlook BCR CVS FLIC suvivorship RKT CSX GOOG APD Share Buybacks NSRGY REITs AMZN UNP POM SIG OXY INGR LKQ ONE Materials SWFT DR ACE RAI OSIS blue-chip Champions ADM CTCM SNH DRI NOG NVS PM investment CPB Stock Research Analysis CINF D ZBRA QCOM LINE DollarCostAverging KMP high-yield ABT MCHP MAN NTES CLX true worth EXLS retirement MCD HCN SLGN RSG VFC BEAV COO PCL PBI DividendChampions SYT TMP MKC MYL BAP FAST Graphs Overvalued ABBV WLP SUBX KFT CTG healthcare MATW intrinsic value,stocks,earnings,fundamentals,stock research tool,due diligence investing for income FTI,HTZ UNH FAST DIS value trap HON GPCM Aristocrat SON ACQ GEOS POWR CNC EK AIG HOG BAC CLR VVC CB C WFM BDX X dividends CMI FAF MDT FCFS P dividend paying cashflow HSNI ETP market timing SBUX marketvaluation BANF LTM JRN INTC free cash flow O suvivorship basis AMP DAN DDS ACI GNTX IBM DHR SJM ETR SCL JPM FOMC AMBN Macro view GILD fast-growing APH InterestRates PRGO ABC GIS GT SHR BigFive,Canadian SAM JOY Dividend Ideas best-of-breed total return K ANTM CLX,EMR RRD ITC cash flow WBA NPM ASNA POR technology INFY fair valuation DOM AET HCBK Utilities WY HIBB BCOR WWW due diligence ENSG TAC TWGP ADP XOM BLL Bond,TGT,UTX CHS OII US Economy ODFL investing stock research tool DELL HE utility DOW FF AGLP HP XRX CL ED:SCG PB CSL AM mid-sized CE DPS ACOM GAS CKSW MELI KO,CLX,CELG,JCP,GT,MSI,PEP,ED PAG NC BMTC TXT BCE beta AB RRC MRK MNR TNGO THRM FRAN ENDP BOBE F ECL COP KMB TIS dividend-growth dividend paying stocks ROST JWN DVA CBRL BNS TGT BLK AMGN DividendIncome MHS GMCR CRI CIO V OUTR biotech DMRC BOKF OGE PNRA RJF OZRK SNI value CHE DTEGY ATW SEIC WU MCY MNTX HRL TRV CVX,SWK,MCD,TGT,PG,WMT,JNJ,MDT,AFT,T,ED ALTE FBHS AA GWW act TIF UEPS SNCR AFL WRLD CERN CASY BPL UL BH AFAM AXP hyper growth stocks KMT EWBC DNB RS WEC banks LEN MNK DFS CTSH PFE CCK AEP HighQuality ABM VMI CAT VCO WMT,ROST,GIS,GE,JNJ,KO EE economy SYNA market stock research KALU ROSE MCK INWK AMG Yield NROM LL NFLX FB CHD THC LH CVX MO INT HSY market currents intrinsicvalue dividend-paying AEG MIDD Utilities Sector WVR JCOM growth AZO ITW FRED COL MSCC BG TE capital appreciation SPLS utility stocks RTN regional banks BHB PNW AMAG JNJ GES FinancialSector FL DTE

Archive

Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”